4.8 Article

Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia

Journal

CANCER CELL
Volume 34, Issue 6, Pages 906-+

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2018.11.002

Keywords

-

Funding

  1. Anthony Rothe Memorial Trust [RRE/0700:bm]
  2. Priority-Driven Collaborative Cancer Research Scheme [1129129]
  3. Cancer Institute NSW
  4. Balnaves Foundation (Young Researchers Fund)
  5. National Health and Medical Research Council of Australia (NHMRC Fellowship) [APP1059804]
  6. NHMRC [1042934, 1102589]
  7. Cancer Australia
  8. Kids' Cancer Project

Ask authors/readers for more resources

Glucocorticoids play a critical role in the treatment of lymphoid malignancies. While glucocorticoid efficacy can be largely attributed to lymphocyte-specific apoptosis, its molecular basis remains elusive. Here, we studied genome-wide lymphocyte-specific open chromatin domains (LSOs), and integrated LSOs with glucocorticoid-induced RNA transcription and chromatin modulation using an in vivo patient-derived xenograft model of acute lymphoblastic leukemia (ALL). This led to the identification of LSOs critical for glucocorticoid-induced apoptosis. Glucocorticoid receptor cooperated with CTCF at these LSOs to mediate DNA looping, which was inhibited by increased DNA methylation in glucocorticoid-resistant ALL and non-lymphoid cell types. Our study demonstrates that lymphocyte-specific epigenetic modifications pre-determine glucocorticoid resistance in ALL and may account for the lack of glucocorticoid sensitivity in other cell types.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available